AdipoGen Life Sciences COVID-19 antiviral research compounds
There are no approved drugs to treat the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19). Existing drugs, which have a known favourable safety profile, are being examined for strategies to treat the disease and fast-track a treatment plan. Several influenza and HIV drugs are currently undergoing clinical trial in coronavirus patients. The rational selection of drugs already on the market is being made based on their ability to inhibit any proteins essential for virus-receptor interaction and/or viral life cycle.
AdipoGen Life Sciences’ range of Small Molecule SARS-CoV-2 Inhibitors and Modulators offers potential tools for in vitro studies of COVID-19. The company’s product range includes research compounds targeting viral transcription, replication and maturation.
Phone: 02 9698 2022
Cayman Chemical Kinase Screening Library (96-Well)
Cayman Chemical's Kinase Screening Library (96-Well) consists of two plates and contains...
AdipoGen Life Sciences GLP-1, GIP and GCG receptor agonists
AdipoGen's range of GLP-1, GIP and GCG receptor agonists includes Liraglutide, Retatrutide,...
Integrated DNA Technologies xGen Hybridization and Wash v3 Kit
Integrated DNA Technologies (IDT) has unveiled its xGen Hybridization and Wash v3 Kit — a...
